Clinical Trial Update: A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared With Intravitreal Aflibercept in Participants With Neovascular (Wet) Age-related Macular Degeneration (wAMD) [Phase 3]

View source ↗

Summary

Phase 3 head-to-head trial evaluating intravitreal KSI-301 versus intravitreal aflibercept in wet age-related macular degeneration has completed with results po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• KSI-301 (KSI-301)

Snippet

Sponsor: Kodiak Sciences Inc | Conditions: Wet Age-related Macular Degeneration | Phase 3 | Status: COMPLETED | Results posted: 2024-05-02